All questions are shown as received by the Trust.
Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.
Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:
a. Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)
b. Bortezomib, thalidomide and dexamethasone [VTD]
c. Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone
d. Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)
e. Selinexor, Bortexomiv [Velcade] and dexamethasone
f. Carfilzomib [Kyprolis] and dexamethasone
g. Bortezomib [Velcade] monotherapy or with dexamethasone
h. Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)
i. Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone
j. Belantamab Mafodotin [Blenrep]
k. Idecabtagene vicleucel [Abecma]
l. Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)
m. Elranatamab
n. Daratumumab [Darzalex] monotherapy
o. Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)
p. Lenalidomide [Revlimid] and dexamethasone
q. Lenalidomide [Revlmid] monotherapy
r. Pomalidomide [Imnovid] and dexamethasone
s. Selinexor and dexamethasone
t. Talquetamab
u. Teclistamab [Tecvayli]
v. Any other systemic anti-cancer therapy
